BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 12827291)

  • 1. A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies.
    Twelves C; Reck M; Anthoney A; Gatzemeier U; Kaye S
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):277-81. PubMed ID: 12827291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.
    Stathopoulos GP; Rigatos SK; Christodoulou C; Malamos NA; Deliyiannis F; Stathopoulos JG; Skarlos DV
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):259-64. PubMed ID: 15127231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
    Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
    Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
    Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
    Sekine I; Sumi M; Ito Y; Kato T; Fujisaka Y; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Jpn J Clin Oncol; 2007 Mar; 37(3):175-80. PubMed ID: 17452427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer.
    Hara T; Omura K; Hirano M; Asada Y; Munemoto Y; Sakamoto J
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):631-6. PubMed ID: 16924496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
    Nemunaitis J; Cunningham C; Senzer N; Gray M; Oldham F; Pippen J; Mennel R; Eisenfeld A
    Cancer Invest; 2005; 23(8):671-6. PubMed ID: 16377585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
    Mita AC; Olszanski AJ; Walovitch RC; Perez RP; MacKay K; Tuck DP; Simmons C; Hammond S; Mita MM; Beeram M; Stone AJ; Rowinsky EK; Lewis LD
    Clin Cancer Res; 2007 Jun; 13(11):3293-301. PubMed ID: 17545535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
    Fabi A; Barduagni M; Ferraresi V; Cortesi E; Gamucci T; De Marinis F; Saltarelli R; Gabriele A; Pellicciotta M; Ceribelli A; De Marco S; Facciolo F; Cognetti F
    J Exp Clin Cancer Res; 2004 Mar; 23(1):25-32. PubMed ID: 15149147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer.
    Hokita S; Aikou T; Miyazono F; Ishigami S; Aridome K; Maenohara S; Saihara T; Suenaga K; Nomura H; Maeda S; Takatori H; Arima H; Uchikado Y; Natsugoe S; Takao S
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):736-40. PubMed ID: 16163539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly paclitaxel and carboplatin with concurrent radiation therapy in locally advanced non-small cell lung cancer: phase I study.
    Endo M; Takada Y; Obayashi K; Kotani Y; Satouchi M; Kado T; Sugimura K
    Radiat Med; 2005 Aug; 23(5):331-5. PubMed ID: 16342905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
    Hasegawa Y; Takanashi S; Okudera K; Aoki M; Basaki K; Kondo H; Takahata T; Yasui-Furukori N; Tateishi T; Abe Y; Okumura K
    Jpn J Clin Oncol; 2004 Nov; 34(11):647-53. PubMed ID: 15613553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
    Kalbakis K; Pappas P; Kouroussis C; Vamvakas L; Kalykaki A; Vardakis N; Nikolaidou M; Marselos M; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):449-56. PubMed ID: 17960381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
    Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.